NASDAQ:WVE - Wave Life Sciences Stock Price, Price Target & More

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) issued its earnings results on Wednesday, May, 9th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.36. The company had revenue of $1.42 million for the quarter, compared to analysts' expectations of $6.59 million. Wave Life Sciences had a negative return on equity of 76.93% and a negative net margin of 2,613.03%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Wave Life Sciences.

4 brokerages have issued 12-month target prices for Wave Life Sciences' stock. Their predictions range from $40.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $56.75 in the next year. View Analyst Ratings for Wave Life Sciences.

Some companies that are related to Wave Life Sciences include Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH) and Array Biopharma (ARRY).

Media stories about WVE stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Wave Life Sciences earned a media sentiment score of 0.06 on Accern's scale. They also assigned headlines about the company an impact score of 46.64 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Wave Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), Redmile Group LLC (7.69%), BB Biotech AG (3.08%), BlackRock Inc. (3.01%) and Eventide Asset Management LLC (1.30%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, BlackRock Inc., Point72 Asset Management L.P., Eventide Asset Management LLC, Bailard Inc., Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and A.R.T. Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Artal Group S.A., DAFNA Capital Management LLC, BB Biotech AG, Platinum Investment Management Ltd., Redmile Group LLC, Citadel Advisors LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $43.55.

Wave Life Sciences has a market capitalization of $1.47 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]